B
Bull
Bull · 25%CNTB
$1.88
Precio del escenario
$2.230
-0.049 (-2.19%)Al cierre
Loading chart…
- High
- 2.320
- Open
- 2.320
- VWAP
- 2.25
- Vol
- 340.77K
- Mkt Cap
- 70.53M
- Low
- 2.200
- Amount
- 766.72K
- EV/EBITDA, TTM
- -0.21
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
AI analysis of Connect Biopharma Holdings Ltd (CNTB)
buyConnect Biopharma Holdings Ltd is a good buy right now due to its upcoming Phase 2 trial results for Rademikibart, expected to be a significant catalyst for the stock. The current price is $2.23, and analysts have set price targets of $6 to $8, indicating substantial upside potential of 169% to 259%. Additionally, the stock has a forward P/E ratio of 0.7669, suggesting it is undervalued compared to its future earnings potential. However, the main risk is the company's negative net income, which was -$17,284,000 in the latest quarter, indicating ongoing financial challenges that investors should monitor closely.
Métricas de valoración
The current forward P/E ratio for Connect Biopharma Holdings Ltd (CNTB) is 0.77, compared to its 5-year average forward P/E of -2.42.
Alphio AI Price Scenarios for CNTB
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding CNTB
Cronología de eventos
Noticias
2.007-10NASDAQ.COMVirax Biolabs Partners with Fosun Diagnostics, Shares Surge
6.006-26CNBCMajor Wall Street Rating Changes on Friday
4.506-03NASDAQ.COMBiotech Stocks Pre-Market Trading Insights
9.004-24NASDAQ.COMConnect Biopharma Initiates Phase 2 Trial for Rademikibart in Asthma and COPD
8.504-03NASDAQ.COMBiotech Landscape Update: Regulatory Approvals and Acquisitions
CNTB FAQ — answered by Alphio AI
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Connect Biopharma Holdings Ltd is a good buy right now due to its upcoming Phase 2 trial results for Rademikibart, expected to be a significant catalyst for the stock. The current price is $2.23, and analysts have set price targets of $6 to $8, indicating substantial upside potential of 169% to 259%. Additionally, the stock has a forward P/E ratio of 0.7669, suggesting it is undervalued compared to its future earnings potential. However, the main risk is the company's negative net income, which was -$17,284,000 in the latest quarter, indicating ongoing financial challenges that investors should monitor closely.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.